News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,712 Results
Type
Article (8025)
Company Profile (140)
Press Release (476546)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166767)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52878)
Employer Resources (14)
FDA (9761)
Job Trends (8576)
News (238254)
Policy (17922)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33161)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10379)
Artificial intelligence (321)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6964)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3653)
Cardiovascular disease (218)
Career advice (246)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47880)
Collaboration (1245)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (757)
CRISPR (63)
C-suite (751)
Cystic fibrosis (86)
Data (5662)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4186)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73717)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87632)
Executive appointments (702)
FDA (12399)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (919)
Gene editing (126)
Generative AI (9)
Gene therapy (319)
GLP-1 (290)
Government (951)
Grass and pollen (2)
Guidances (281)
Healthcare (9330)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (102)
Immuno-oncology (56)
Indications (157)
Infectious disease (945)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (255)
Interviews (42)
IPO (12391)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (60)
Legal (5209)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (534)
Marketing (8)
MASH (118)
Medical device (8657)
Medtech (8802)
Mergers & acquisitions (14386)
Metabolic disorders (710)
mRNA (55)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (221)
Neuropsychiatric disorders (40)
Neuroscience (1827)
NextGen: Class of 2026 (3153)
Non-profit (846)
Obesity (226)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (508)
Peanut (31)
People (41258)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15470)
Phase 2 (21384)
Phase 3 (14401)
Pipeline (7345)
Policy (18)
Postmarket research (1572)
Preclinical (6539)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3021)
Recruiting (6)
Regulatory (14840)
Reports (21)
Research institute (582)
Resumes & cover letters (46)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (50)
Vaccines (323)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (46)
Last 7 days (216)
Last 30 days (1581)
Last 365 days (19045)
2026 (12346)
2025 (19252)
2024 (22988)
2023 (26541)
2022 (34588)
2021 (37179)
2020 (33479)
2019 (23275)
2018 (17493)
2017 (18765)
2016 (17920)
2015 (24263)
2014 (21683)
2013 (18138)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17893)
Australia (2098)
California (11988)
Canada (3148)
China (524)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24629)
Florida (1789)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (700)
India (51)
Indiana (314)
Iowa (15)
Japan (403)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7861)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2822)
North Carolina (1280)
North Dakota (4)
Northern California (6003)
Ohio (278)
Oklahoma (14)
Oregon (16)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4983)
Tennessee (120)
Texas (1942)
United States (38901)
Utah (360)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,712 Results for "evommune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.
June 30, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 7, 2026
·
9 min read
Press Releases
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
July 30, 2026
·
6 min read
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical trial.
February 10, 2026
·
1 min read
·
Dan Samorodnitsky
Press Releases
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
June 29, 2026
·
6 min read
Press Releases
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 8, 2026
·
10 min read
Press Releases
Evommune Announces $125 Million Private Placement
February 12, 2026
·
5 min read
IPO
Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
October 31, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
April 6, 2026
·
2 min read
Press Releases
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 5, 2026
·
10 min read
1 of 48,472
Next
